EyePoint Pharmaceuticals completes enrollment for the LUCIA trial, advancing DURAVYU's potential as a new treatment for wet AMD. EyePoint Pharmaceuticals recently announced the completion of ...

Boehringer Ingelheim initiates THULITE study, exploring an oral treatment for diabetic macular edema, aimed to improve patient care and convenience. Affecting more than 21 million people globally, DME ...

Curacle plans to finalize its development strategy, including phase 2b and 3 trials, through a Type C meeting with the US FDA in February of 2025. Curacle presented the results of its phase 2a ...

At the 2025 American Society of Retina Specialists (ASRS) meeting in Long Beach, California, Yasha S. Modi, MD, associate professor of ophthalmology at NYU Langone, presented end-of-study results from ...

In her keynote address, Prof Schmidt-Erfurth focused on new artificial intelligence tools and their usage in addressing age-related macular degeneration. At this year's meeting of the European Society ...

The completion of the full BLA submission is anticipated in early 2026 and is eligible for priority review under the program’s fast-track designation. Today Nanoscope Therapeutics announced its ...

The company expects approval from the EMA by 2025. Altos Biologics Inc. has submitted the Marketing Authorization Application to the European Medicines Agency (EMA) for ALT-L9, an aflibercept ...

This phase 2b study (ASPIRE) is currently underway. UNITY believes that its lead candidate, UBX1325 (foselutoclax), with its unique mechanism of action, has the potential to improve long-term visual ...

At this year's ARVO meeting, Deborah A Ferrington, MD, PhD, presented "Genotype-specific differences in mitochondrial function specific to the CFH Y402H risk allele associated with AMD." At this ...

Although my practice is primarily an anterior segment practice, the care of patients with age-related macular degeneration (AMD) is something I have always followed closely. AMD is the leading cause ...

The study saw encouraging results and helped to identify suitable dosing levels for future clinical trials. OliX Pharmaceuticals, Inc. announced positive results from a phase 1 study of the safety and ...

The results of a new retrospective cohort study suggest that use of curcuma-based nutritional supplements (CBNS) may be associated with the reduced risk of developing age-related macular degeneration ...